

10/581569

Express Mail No. EV668295392US

Date of Deposit: June 2, 2006

SLR:dm 06/01/06 5585-68214-02 534273 RCD/P104185US

1AP20 Rec'd PCT/PTO 02 JUN 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Xin Lu and Nadia Godin-Heymann

Application No. Currently unknown

Filed: Herewith

Confirmation No. Currently unknown

For: SCREENING ASSAY AND TREATMENT

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 5585-68214-02

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(1)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.


Applicants filed this Information Disclosure Statement ("IDS") within three months of the filing date of a national application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. § 1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

cc: Docketing

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	5585-68214-02
Application Number	10/581569
Filing Date	June 2, 2006
First Named Inventor	Lu
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 02/12325	02/14/2002	Ludwig Institute for Cancer Research

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Bergamaschi et al., "iASPP Oncoprotein is a Key Inhibitor of p53 Conserved from Worm to Human," <i>Nature Genetics</i> 33:162-167 (2003).
		Helps et al., "Protein Phosphatase 1 Interacts with p53BP2, a Protein which Binds to the Tumor Suppressor p53," <i>FEBS Lett.</i> 377:295-300 (1995).
		Iwabuchi et al., "Stimulation of p53-Medicated Transcriptional Activation by the p53-Binding Proteins, 53BP1 and 53BP2," <i>J. Biol. Chem.</i> 273:26061-26068 (1998).
		Laird et al., "Oncoprotein Signalling and Mitosis," <i>Cell. Signal.</i> 9:249-255 (1997).
		Samuels-Lev et al., "ASPP Proteins Specifically Stimulate the Apoptotic Function of p53," <i>Mol. Cell</i> 8:781-794 (2001).
		Slee et al., "The ASPP Family: Deciding Between Life and Death After DNA Damage," <i>Toxicol. Lett.</i> 139:81-87 (2003).

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.